Drug · DIN 02231379
ANZEMET
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since April 21, 2014; first marketed August 15, 1997.
- Drug Identification Number (DIN)
- 02231379
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Dolasetron A04AA04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DOLASETRON MESYLATE | 100 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 4, 2006: NOC 7931New Drug Submission (NDS) · Manufacturer name change
- June 16, 2000: NOC 1105New Drug Submission (NDS)
- May 21, 1997: NOC 3731New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “anzemet”. A notice may cover another product or only some lots: read it to see what it covers.
- ANZEMET (dolasetron mesylate) – Withdrawal of 20 mg/mL Intravenous Injection Due to Potential Risk of Arrhythmias – For the PublicApril 28, 2011 · Drugs
- ANZEMET (dolasetron mesylate) - Withdrawal of 20 mg/mL Intravenous Injection Due to Potential Risk of Arrhythmias - For Health ProfessionalsApril 28, 2011 · Drugs
- Important Safety Information on Anzemet (dolasetron mesylate): New Contraindications - Notice to HospitalsJune 30, 2006 · Drugs
Other DINs named ANZEMET
- DIN 02231378 · Cancelled Post Market